Anti-CD4 treatment increases tumor-suppressive IL18Rαhi CD8+ T cells

ABSTRACT: Anti-CD4 monoclonal antibody, a prominent immunomodulatory agent, elicits robust anti-tumor immunity in various cancers by increasing tumor-infiltrating lymphocytes and promoting CD8+ T cell reactivity against tumor cell-derived antigens. We conducted single-cell transcriptome analysis of anti-CD4-exposed lymphoid cells to investigate the detailed mechanism.

ORGANISM(S): Mus musculus

PROVIDER: GSE180991 | GEO | 2021/07/30

REPOSITORIES: GEO